ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,920.10
0.29%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Galera Therapeutics Inc (GRTX)

  7. Galera Therapeutics Inc (GRTX) Noticias

GRTX

Galera Therapeutics (GRTX)

Galera Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GRTX
FechaHoraFuenteTítuloSímboloCompañía
16/05/202409:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GRTXGalera Therapeutics Inc
16/05/202409:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRTXGalera Therapeutics Inc
16/05/202409:25Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:GRTXGalera Therapeutics Inc
13/05/202406:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GRTXGalera Therapeutics Inc
13/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GRTXGalera Therapeutics Inc
13/05/202406:00GlobeNewswire Inc.Galera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesNASDAQ:GRTXGalera Therapeutics Inc
03/05/202406:00GlobeNewswire Inc.Galera Adopts Limited Duration Stockholder Rights AgreementNASDAQ:GRTXGalera Therapeutics Inc
28/03/202406:00GlobeNewswire Inc.Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesNASDAQ:GRTXGalera Therapeutics Inc
26/02/202415:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GRTXGalera Therapeutics Inc
20/02/202417:57Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:GRTXGalera Therapeutics Inc
14/11/202306:00GlobeNewswire Inc.Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:GRTXGalera Therapeutics Inc
31/10/202307:09Dow Jones NewsGalera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 TrialNASDAQ:GRTXGalera Therapeutics Inc
31/10/202306:00GlobeNewswire Inc.Galera Announces Receipt of Type A Meeting Minutes and Strategic UpdateNASDAQ:GRTXGalera Therapeutics Inc
18/09/202306:00GlobeNewswire Inc.Galera Schedules Type A Meeting with FDA to Discuss Next Steps for AvasopasemNASDAQ:GRTXGalera Therapeutics Inc
05/09/202306:00GlobeNewswire Inc.Galera to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:GRTXGalera Therapeutics Inc
14/08/202306:00GlobeNewswire Inc.Galera Reports Second Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:GRTXGalera Therapeutics Inc
09/08/202319:10Dow Jones NewsStocks to Watch: Applovin, Disney, Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics Inc
09/08/202316:23Dow Jones NewsGalera Therapeutics to Reduce Workforce by 70% to Extend Cash RunwayNASDAQ:GRTXGalera Therapeutics Inc
09/08/202315:31GlobeNewswire Inc.Galera Receives Complete Response Letter from U.S. FDA for Avasopasem ManganeseNASDAQ:GRTXGalera Therapeutics Inc
28/06/202315:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GRTXGalera Therapeutics Inc
16/06/202315:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GRTXGalera Therapeutics Inc
05/06/202313:15GlobeNewswire Inc.Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual MeetingNASDAQ:GRTXGalera Therapeutics Inc
18/05/202307:44Dow Jones NewsGalera Therapeutics Gets Orphan Drug Designation for RucosopasemNASDAQ:GRTXGalera Therapeutics Inc
18/05/202307:00GlobeNewswire Inc.Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic CancerNASDAQ:GRTXGalera Therapeutics Inc
11/05/202315:08Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GRTXGalera Therapeutics Inc
11/05/202306:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GRTXGalera Therapeutics Inc
11/05/202306:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GRTXGalera Therapeutics Inc
11/05/202306:00GlobeNewswire Inc.Galera Reports First Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:GRTXGalera Therapeutics Inc
04/05/202315:01GlobeNewswire Inc.Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GRTXGalera Therapeutics Inc
01/05/202306:00GlobeNewswire Inc.Galera Expands Commercial Leadership TeamNASDAQ:GRTXGalera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GRTX

Su Consulta Reciente

USOTC
AVMR
AVRA Medical Robotics (PK)
BIT
P1WTZ2
NLBNPIT1WTZ2 20240918 15...
OKEX
DPYETH
USOTC
ELEAF
EL EN SPA Firenze (PK)
BIT
P20RE7
NLBNPIT20RE7 20351221 3....
BIT
NSCIT0011816
Nederland
BIT
CNF
Conafi
NASDAQ
ACGLN
Arch Capital
EU
BPAAD
Banque Palatine Bpafrn27...
NASDAQ
ABABKXX
Bank of Montreal Capped ...
EU
BQPEQ
La Banque Postale Home L...
COIN
FITKRW
300FIT Network
COIN
SSNNUST
Supersonic
UNSW3
THALESETH
Thales DAO Token
LBNK
BRKUSDT
BRKToken
BIT
P166W8
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados